1215626-40-6

Basic information

• Product Name: methyl 5-(4-(tert-butoxycarbonyl)piperazin-1-yl)pyrazine-2-carboxylate
• Synonyms: methyl 5-(4-(tert-butoxycarbonyl)piperazin-1-yl)pyrazine-2-carboxylate
• CAS NO: 1215626-40-6
• Molecular Formula: C15H22N4O4
• Molecular Weight: 322.364
• Mol File: 1215626-40-6.mol

Chemical Properties

• CAS DataBase Reference: methyl 5-(4-(tert-butoxycarbonyl)piperazin-1-yl)pyrazine-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 5-(4-(tert-butoxycarbonyl)piperazin-1-yl)pyrazine-2-carboxylate(1215626-40-6)
• EPA Substance Registry System: methyl 5-(4-(tert-butoxycarbonyl)piperazin-1-yl)pyrazine-2-carboxylate(1215626-40-6)

Safety Data

• Hazardous Substances Data: 1215626-40-6(Hazardous Substances Data)

Upstream product

• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 23611-75-8 6-chloro-pyrazine-2-carboxylic acid methyl ester 
• 34604-60-9 5-hydroxypyrazinoic acid 
• 33332-25-1 methyl 5-chloropyrazine-2-carboxylate 

Downstream Products

• 1360552-50-6 5'-(3-{1-[4-(2-amino-pyrimidin-5-yl)-phenyl]-1-cyclopropyl-ethyl}-[1,2,4]oxadiazol-5-yl)-2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4-carboxylic Acid tert-butyl ester 
• 1209646-17-2 5-(4-(tert-butoxycarbonyl)piperazin-1-yl) pyrazine-2-carboxylic acid 
• 1360552-49-3 C₂₆H₃₁BrN₆O₃ 
• 1360552-55-1 C₂₆H₃₁BrN₆O₃ 
• 1360552-56-2 5'-(3-{(S)-1-[4-(5-amino-pyrazin-2-yl)-phenyl]-1-cyclopropyl-ethyl}-[1,2,4]oxadiazol-5-yl)-2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4-carboxylic Acid tert-butyl Ester 
• 1361190-35-3 5'-(3-{1-[4-(2-amino-pyrimidin-5-yl)-phenyl]-cyclobutyl}-[1,2,4]oxadiazol-5-yl)-2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4-carboxylic acid tert-butyl ester 
• 1361189-31-2 5-(4-{1-[5-(3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-5'-yl)-[1,2,4]oxadiazol-3-yl]-cyclobutyl}-phenyl)pyrazin-2-ylamine 
• 1361189-25-4 5-(4-{1-[5-(3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-5'-yl)-[1,2,4]oxadiazol-3-yl]-cyclobutyl}-phenyl)pyridin-2-ylamine 
• 1361187-57-6 5-(4-{1-[5-(3,4,5,6-tetrahydro-2H-1,2'-bipyrazinyl-5'-yl)-1,2,4-oxadiazol-3-yl]-cyclobutyl}-phenyl)-pyrimidin-2-ylamine 

Relevant articles and documents

Chemo-selective syntheses of: N-t -boc-protected amino ester analogs through Buchwald-Hartwig amination

The synthesis of N-protected amino esters is achieved via a chemo-selective Buchwald Hartwig cross-coupling reaction using PEPPSI-IPr Pd-catalyst. Nearly two dozen functionally and structurally diverse amino ester molecules are created by individually cross-coupling eight aryl halo esters and three different secondary amines. We observed that product formation is more facile in those heterocyclic esters where nitrogen is present ortho to the halo substituent in the heteroaromatic ring. Based on this observation, we propose a possible intermediate step in the cross-coupling cycle, where the nitrogen electron lone pair in the heterocycle may play an important role leading to a higher reaction yield.

BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF

The present disclosure provides bifunctional compounds as HPK1 degraders via ubiquitin proteosome pathway, and method for treating diseases modulated by HPK1.

COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR

This disclosure pertains to compounds, the preparation thereof, and the use of these compounds in the treatment of prostate cancer, including metastatic and/or castrate-resistant prostate cancer, in subjects in need thereof.

HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE

Provided herein are certain compounds useful as HTT modulators. Such compound are useful in the treatment of Huntington's disease.

PYRIMIDINE AND PYRAZINE HDAC1,2 INHIBITORS

Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.

SELECTIVE HDAC1,2 INHIBITORS

Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.

OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION FOR COMBINATION THERAPY

The present invention relates to combination therapy using compound of formula (I): or pharmaceutically acceptable salts thereof, wherein R1-R5 are as defined herein and an additional pharmaceutically active agent. The invention also relates to pharmaceutical compositions comprising these combinations, and methods of using these combinations in the treatment of various diseases and disorders.

OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION

The present invention relates to compound of formula (I): or pharmaceutically acceptable salts thereof, wherein R1-R5 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION

The present invention relates to compound of formula (I) and pharmaceutically acceptable salt thereof, wherein R1-R5 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION

The present invention relates to compounds of formula (I) and (IA) and pharmaceutically acceptable salts thereof, wherein R1- R5 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.